vs
Apellis Pharmaceuticals, Inc.（APLS）与1ST SOURCE CORP（SRCE）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是1ST SOURCE CORP的1.8倍（$199.9M vs $113.1M），1ST SOURCE CORP净利率更高（35.3% vs -29.5%，领先64.8%），1ST SOURCE CORP同比增速更快（8.7% vs -5.9%），1ST SOURCE CORP自由现金流更多（$58.1M vs $-14.3M），过去两年1ST SOURCE CORP的营收复合增速更高（7.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
第一来源公司（1st Source Corporation）是总部位于美国印第安纳州南本德的金融服务企业，旗下运营第一来源银行，在印第安纳州和密歇根州拥有81家分支机构，其专业金融团队为飞机、卡车、工程设备提供融资服务，同时还通过第一来源保险板块提供各类保险产品及相关服务。
APLS vs SRCE — 直观对比
营收规模更大
APLS
是对方的1.8倍
$113.1M
营收增速更快
SRCE
高出14.7%
-5.9%
净利率更高
SRCE
高出64.8%
-29.5%
自由现金流更多
SRCE
多$72.4M
$-14.3M
两年增速更快
SRCE
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $113.1M |
| 净利润 | $-59.0M | $40.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 45.4% |
| 净利率 | -29.5% | 35.3% |
| 营收同比 | -5.9% | 8.7% |
| 净利润同比 | -62.2% | 6.5% |
| 每股收益（稀释后） | $-0.40 | $1.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSRCE
| Q1 26 | — | $113.1M | ||
| Q4 25 | $199.9M | $110.8M | ||
| Q3 25 | $458.6M | $110.7M | ||
| Q2 25 | $178.5M | $108.2M | ||
| Q1 25 | $166.8M | $104.0M | ||
| Q4 24 | $212.5M | $97.8M | ||
| Q3 24 | $196.8M | $97.9M | ||
| Q2 24 | $199.7M | $97.3M |
净利润APLSSRCE
| Q1 26 | — | $40.0M | ||
| Q4 25 | $-59.0M | $41.1M | ||
| Q3 25 | $215.7M | $42.3M | ||
| Q2 25 | $-42.2M | $37.3M | ||
| Q1 25 | $-92.2M | $37.5M | ||
| Q4 24 | $-36.4M | $31.4M | ||
| Q3 24 | $-57.4M | $34.9M | ||
| Q2 24 | $-37.7M | $36.8M |
营业利润率APLSSRCE
| Q1 26 | — | 45.4% | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 49.7% | ||
| Q2 25 | -18.6% | 44.5% | ||
| Q1 25 | -50.0% | 45.8% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 46.3% | ||
| Q2 24 | -14.7% | 49.1% |
净利率APLSSRCE
| Q1 26 | — | 35.3% | ||
| Q4 25 | -29.5% | 37.1% | ||
| Q3 25 | 47.0% | 38.2% | ||
| Q2 25 | -23.6% | 34.5% | ||
| Q1 25 | -55.3% | 36.1% | ||
| Q4 24 | -17.1% | 32.1% | ||
| Q3 24 | -29.2% | 35.7% | ||
| Q2 24 | -18.9% | 37.8% |
每股收益（稀释后）APLSSRCE
| Q1 26 | — | $1.63 | ||
| Q4 25 | $-0.40 | $1.67 | ||
| Q3 25 | $1.67 | $1.71 | ||
| Q2 25 | $-0.33 | $1.51 | ||
| Q1 25 | $-0.74 | $1.52 | ||
| Q4 24 | $-0.30 | $1.27 | ||
| Q3 24 | $-0.46 | $1.41 | ||
| Q2 24 | $-0.30 | $1.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $9.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSRCE
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSSRCE
| Q1 26 | — | $1.3B | ||
| Q4 25 | $370.1M | $1.3B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.0B |
总资产APLSSRCE
| Q1 26 | — | $9.1B | ||
| Q4 25 | $1.1B | $9.1B | ||
| Q3 25 | $1.1B | $9.1B | ||
| Q2 25 | $821.4M | $9.1B | ||
| Q1 25 | $807.3M | $9.0B | ||
| Q4 24 | $885.1M | $8.9B | ||
| Q3 24 | $901.9M | $8.8B | ||
| Q2 24 | $904.5M | $8.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $59.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $58.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 51.4% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $361.4M |
8季度趋势，按日历期对齐
经营现金流APLSSRCE
| Q1 26 | — | $59.1M | ||
| Q4 25 | $-14.2M | $223.1M | ||
| Q3 25 | $108.5M | $51.0M | ||
| Q2 25 | $4.4M | $44.9M | ||
| Q1 25 | $-53.4M | $71.8M | ||
| Q4 24 | $19.4M | $193.9M | ||
| Q3 24 | $34.1M | $68.4M | ||
| Q2 24 | $-8.3M | $50.0M |
自由现金流APLSSRCE
| Q1 26 | — | $58.1M | ||
| Q4 25 | $-14.3M | $213.0M | ||
| Q3 25 | $108.3M | $47.3M | ||
| Q2 25 | $4.4M | $43.0M | ||
| Q1 25 | $-53.4M | $69.3M | ||
| Q4 24 | $19.3M | $181.5M | ||
| Q3 24 | — | $66.7M | ||
| Q2 24 | $-8.4M | $46.4M |
自由现金流率APLSSRCE
| Q1 26 | — | 51.4% | ||
| Q4 25 | -7.1% | 192.2% | ||
| Q3 25 | 23.6% | 42.7% | ||
| Q2 25 | 2.5% | 39.8% | ||
| Q1 25 | -32.0% | 66.6% | ||
| Q4 24 | 9.1% | 185.5% | ||
| Q3 24 | — | 68.1% | ||
| Q2 24 | -4.2% | 47.7% |
资本支出强度APLSSRCE
| Q1 26 | — | 0.9% | ||
| Q4 25 | 0.1% | 9.1% | ||
| Q3 25 | 0.0% | 3.4% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 12.6% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 3.7% |
现金转化率APLSSRCE
| Q1 26 | — | 1.48× | ||
| Q4 25 | — | 5.42× | ||
| Q3 25 | 0.50× | 1.21× | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 1.91× | ||
| Q4 24 | — | 6.17× | ||
| Q3 24 | — | 1.96× | ||
| Q2 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SRCE
暂无分部数据
